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Abstract
Background.To determine if clinical correlates of knee osteoarthritis(OA) affect likelihood of outcome to 
intra-articular steroid injections(IASI) in symptomatic knee OA.  
Method.Men and women aged≥40 years with painful knee OA who participated in an open label trial of 
IASI completed questionnaires and clinical examination. OMERACT-OARSI criteria were used to assess 
response to therapy in the short-term(within 2-weeks). Among those who initially responded, those whose 
pain had not returned to within 20% of the baseline KOOS-pain score at 6-months were characterised as 
longer-term responders. Log binomial regression was used to examine factors associated with outcome.
Results.199 participants were included, of whom 146(73.4%) were short-term and 40(20.1%) longer-term 
responders. Compared to short-term non-responders, participants with medial joint-line 
tenderness(RR=1.42;1.10-1.82), medial & lateral joint-line tenderness(RR=1.38;1.03-1.84), patellofemoral 
tenderness(RR=1.27;1.04-1.55), anserine tenderness(RR=1.27;1.06-1.52) and a belief that treatment 
would be effective(RR/unit increase, [range 0-10]=1.05;1.01-1.09), were more likely to be short-term 
responders. Aspiration of joint fluid(RR=0.79;0.66-0.95) and previous ligament/meniscus 
injury(RR=0.63;0.44-0.91) were associated with a reduced risk of being a short-term responder. Compared 
to initial non-responders and those whose pain recurred within 6-months, participants with higher number 
of pain sites(RR/unit increase, [range 0-10]=0.83;0.72-0.97), chronic widespread pain(RR=0.32;0.10-0.98), 
perceived chronicity of disease(RR/unit increase, [range 0-10]=0.86;0.78-0.94) and a higher depression 
score(RR/unit increase, [range 0-21]=0.89;0.81-0.99) were less likely to be longer-term responders. 
Conclusion. Among patients with symptomatic knee OA, tenderness around the knee was associated with 
better short-term outcome to IASI. However, clinical-related factors did not predict longer-term response 
while those with chronic widespread pain and depressive symptoms were less likely to obtain longer-term 
benefit. 
Keywords: predictors, knee osteoarthritis, intra-articular steroid injection, clinical tests, 
psychological
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Introduction
Intra-articular steroid injection(IASI) is an effective treatment for many individuals with symptomatic 
osteoarthritis(OA) of the knee with short-term pain-relief lasting up to 4 weeks1-5 and longer-term response 
up to 24 weeks1,6. Previous systematic reviews and meta-analyses have shown there is variation in both 
the magnitude and duration of symptom-relief following steroid injections1,3,7. Evidence from recent 
systematic reviews suggests, however, no factor consistently linked with response7,8. In more recent 
analyses, using an individual patient data meta-analysis of randomized controlled trials, patients with 
severe baseline pain were found to benefit more from a steroid injection than those with less severe pain9. 
The presence of inflammatory signs did not appear to influence outcome9-11. While in a study of 174 
women increasing age, reduced knee range of movement(ROM), increased local knee tenderness and 
more severe radiographic disease were associated with a reduced response to IASI at 3-months12. In a 
recent prospective study in individuals with knee OA, no clinical, radiographic, sonographic and serological 
characteristics influenced response other than female gender which was associated with response at three 
weeks(p=0.045), and previous injection with non-response at nine weeks(p=0.021)11. In a different 
prospective cohort study where repeated IASI were undertaken in predominantly knee OA of Kellgren-
Lawrence(KL) 1-3, patients with persisting pain or ultrasound effusion at 1-month after IASI showed a 
reduced probability to respond to additional injections and to treatment response at 1-year13.
There are few data concerning the impact of psychological factors on treatment response7. In our recent 
open-label study of IASI in knee OA14,15, not all participants responded to the therapy in the short-term. Of 
those who responded, the majority had a recurrence of pain within 6-months. In previous work, we looked 
at the impact of disease severity on outcome following IASI and found that those with more severe 
disease[either magnetic resonance imaging(MRI) or x-ray] were less likely to be longer-term 
responders14,15. The aim of the current study was to determine the impact of a range of clinical correlates of 
disease including symptoms, clinical signs of knee OA, psychologic factors and quality of life, on both 
short-term(within 2-weeks) and longer-term(6-months) outcome following IASI. Our IASI predictor of 
outcome study was larger in scale and longer in follow-up than prior studies, and was also designed to look 
at a more comprehensive list of predictor factors to IASI treatment. 














































Men and women aged 40 years and over were recruited from primary and secondary care for participation 
in an open-label study looking at efficacy of IASI in symptomatic knee OA(ISRCTN: 07329370). 
Participants were included if they reported moderate knee pain for more than 48 hours in the previous 2-
weeks or scored greater than 7 out of 32 on the Knee Injury and Osteoarthritis Outcome Score(KOOS) 
questionnaire, questions P2–P9(question P1 relates to frequency of knee pain, which is irrelevant given the 
inclusion criteria on pain frequency). Inclusion criteria included imaging confirmation of definite knee OA 
either radiologically[KL≥2 on postero-anterior, lateral or skyline view in any knee compartment in the past 2 
years] or, if no x-rays were obtained, evidence of OA on MRI or at arthroscopy. For MRI and arthroscopy, 
typical changes of OA with at least cartilage loss present were required. Exclusion criteria included gout, 
septic arthritis, inflammatory arthritis, hyaluronic acid or steroid injection within the previous 3-months, knee 
surgery within the previous 6-months and concurrent life threatening illnesses14,15. Participants were 
provided with study information sheets and subsequently gave written informed consent if they agreed to 
participate. Ethics approval was received from the Leicestershire Multicentre Research Ethics 
Committee(reference 09/H0402/107). 
Screening and baseline assessment
Participants were assessed for eligibility at a screening visit14. Those who fulfilled the inclusion/exclusion 
criteria were invited to attend a baseline visit. Participants also completed questionnaires including the 
KOOS-pain scale(relating to the index knee) where higher score denotes lower severity of symptoms16, a 
global perception of change-Likert scale, a Visual Analogue Scale(VAS) score for pain during an activity 
that a patient nominated as being most troublesome(VASNA), Short-Form-12(SF-12)17, Hospital Anxiety 
Depression scale(HADS)18 and Illness Perception Questionnaires-Brief(IPQ-B)19. The SF-12 is a validated 
survey designed to assess health status with both mental and physical health-related quality of life20,21. 
HADS is a 14-item scale, scored 0–3 with seven items each, measuring anxiety and depression over the 
last week18. The IPQ-B provides a quantitative assessment of five components of cognitive and emotional 
representations of illness using Leventhal’s Self-Regulatory Model and includes 8 items scored 0–10 with a 
higher score representing stronger belief19. The occurrence of pain at other sites was assessed using a 
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manikin for body pain(4 figures:front, back, left and right side); participants were asked to complete this for 
aches and pain which lasted longer than one day that they experienced in the past month22. A further 
question asked about whether they had been aware of the pain for more than 3-months. Chronic 
Widespread Pain(CWP) was defined as pain experienced in contralateral quadrants of the body, above 
and below the waist and in the axial skeleton that had persisted for more than 3-months23,24. We also noted 
the number of the shaded regions on the manikin to reflect the number of pain sites23,24.
A subsample(n=103) of participants had additional clinical tests performed by one of two assessors prior to 
having their steroid injections using standardised assessment procedures. These additional tests included 
assessment of bony enlargement(absent=0, unsure=1, present=2), joint crepitus(absent=0, unsure=1, 
present palpable=2, present audible=3), quadriceps muscle wasting(absent=0, possible=1, present=2), 
assessment of effusion using the bulge sign25, assessment of effusion using the ballottement 
test(absent=0, present without click=1, present with click (tap)=2), patellofemoral joint 
tenderness(absent=0, present=1), pes anserine tenderness(absent=0, present=1), medial tibiofemoral joint 
tenderness(absent=0, present=1), lateral tibiofemoral joint tenderness(absent=0, present=1) and 
goniometric knee ROM, flexion and extension measured to the nearest degrees26. Maximal voluntary 
isometric strength of the quadriceps was measured by a strain gauge using a protocol developed for past 
studies27. Strength scores were measured as torque in Newton meters(Nm) and normalized for body size 
using the formula corrected strength=Nm/(weight in kg x [height in m divided by 2]). The length of the distal 
lower limb was taken to allow calculation of torque. For the elements of the clinical examination, reliability 
evaluation intra-(К=0.60–0.98;ICC=0.96–0.99) and inter-observer(К=0.48–1.00;ICC=0.87–0.97) showed 
moderate to excellent agreement28. While kappa can be affected by the prevalence, in our study for most 
clinical signs the prevalence was not particularly low. We also asked participants 'Have you ever been told 
you have injured your ligaments or meniscus in your affected knee(yes, no, don't know)'.  
Following the assessments, arthrocentesis was performed with removal of synovial fluid(if present) and 
injection of 80 mg methylprednisolone acetate(without local anaesthetic). The majority of injections were 
undertaken non-guided using a medial approach to the knee joint by one of two experienced 
clinicians(TON/NM). Following further ethics approval, during the course of the study, we used ultrasound 
to guide localisation of the injections for the remaining subjects using lateral approach to the suprapatellar 
bursa(NM). Any participant in whom the synovial fluid white cell count(WCC) was found to be greater than 










































The Journal of on April 15, 2019 - Published by www.jrheum.orgDownloaded from 
7
1,500/mm3 was excluded due to concerns they might have a primary inflammatory arthritis. We treated and 
studied one knee per participant. 
Follow-up 
We defined response to IASI using the OMERACT-OARSI responder criteria based on the KOOS-pain 
scale and global perception of change-Likert scale29. A responder was defined as having either (i)greater 
or equal to 20% change in KOOS-pain score and a “slightly” or “much better” score on the 5-point Likert 
scale for change in pain, or (ii)greater or equal to 50% change in the KOOS-pain score; in both cases an 
absolute change of at least 3 units if the baseline KOOS-pain score was 15 or less. Participants were seen 
usually within 2-weeks after the injection and we characterised their response at that time as short-term 
response. Those who had not responded were not further followed. Those who responded were followed 
with regular telephone calls every 4-weeks during which the same KOOS-pain questions and global-Likert 
scale were administered. Those whose pain recurred to within 20% of the baseline KOOS-pain score were 
defined as having relapsed and were seen again for final follow-up. Those whose pain levels did not return 
to this level at 6-months of follow-up were classified as ‘longer-term responders’.  
Analysis
Means and standard deviations(SD) for normally-distributed variables, and medians and interquartile 
ranges(IQR) for variables with a skewed distribution, were used to summarise participant characteristics. 
Log-binomial regression was used to determine whether baseline factors were associated with both short-
term response(i.e. those who responded within 2-weeks vs those who did not) and longer-term 
response(those who were responders at 6-months vs those who did not respond initially or, who were 
initial responders and whose pain subsequently recurred within 6-months) to therapy. In all the analyses 
the outcome was responder status(yes vs no). All categorical predictors were coded as dummy variables, 
thereby making no assumptions about the relationship between categories, in terms of order(rank) or 
scale. This process was repeated for all categorical predictors, including those with ordinal categories(for 
example, bulge sign). Due to low frequencies in subcategories, the crepitus and ballottement variables 
were collapsed into dichotomous variables, coded as (absent=0, present palpable and/or audible=1), and 
(absent=0, present with/without click=1), respectively. Any factors which were significantly associated with 
outcome were then included in a subsequent multivariable analysis(two models; one for short-term [using 










































The Journal of on April 15, 2019 - Published by www.jrheum.orgDownloaded from 
8
Poisson regression with robust standard errors] and one for longer-term responders[using log-binomial 
regression]) to examine whether associations were retained in the presence of other predictors. Results 
were expressed as Relative Risks(RR) and 95% confidence intervals(CI). No adjustment was undertaken 




209 participants were recruited. Two were withdrawn following recruitment because they received a steroid 
injection from their General Practitioner(Figure 1). Following intervention with IASI, a further 8 were 
withdrawn for a number of reasons as listed in Figure 1. Out of the remaining 199 participants, 103 had 
additional assessments performed. The mean age of the 199 remaining in the study was 62.8 
years(SD=10.3) and 105(52.8%) were female(Table 1a). Median KOOS pain score at baseline was 44.4 
points(IQR=36.1–55.6), and median VASNA was 7.0 cm(IQR=5.6–8.1)(Table 1a). The median time 
between baseline and first follow-up visit was 8 days(IQR=7–14). Median KOOS pain and VASNA at 
baseline, first follow-up and at 6-months stratified by responder status is presented in Table 1a. Other 
participant characteristics including the psychological factors, quality of life and clinical related factors are 
presented in Tables 1a and 1b. The baseline characteristics of subjects who received their injections 
unguided were broadly similar to those who received their injections guided(Table 2). There was no 
difference in the demographic characteristics or pain symptoms in those subjects who had additional 
clinical assessments performed and those who did not(online supplementary table 1). Our findings with 
respect to a subsample(n=120) of participants who had an MRI of their knee performed have been 
published14,15. 
Predictors of Short-Term Responder Status 
Of those participants who had an IASI, 146(73.4%) were defined as short-term responders. Those with 
medial tibiofemoral joint tenderness(RR=1.42;95% CI 1.10–1.82), medial & lateral tibiofemoral joint 
tenderness(RR=1.38;95% CI 1.03–1.84), patellofemoral tenderness(RR=1.27;95% CI 1.04–1.55), or 
anserine tenderness(RR=1.27;95% CI 1.06–1.52), and also those with a positive belief about treatment 
with IASI(IPQ-B Treatment Score)(RR per unit increase=1.05;95% CI 1.01–1.09) were more likely to be 
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responders, while aspiration of synovial fluid(RR=0.79;95% CI 0.66–0.95) and previous ligament or 
meniscus injury(RR=0.63;95% CI 0.44–0.91) were associated with a reduced likelihood of being a short-
term responder(Table 3 and 4). None of the other patient-related factors including the use of guided 
injection, psychological factors, quality of life or clinical signs of disease was linked with short-term 
responder status(Table 3 and 4). In a multivariable analysis of the factors that were associated with short-
term response only one factor(previous ligament or meniscus injury) remained significant after adjustment 
(online supplementary table 2).
Predictors of Longer-Term Responder Status (6-months)
40 participants from those who were short-term responders(20.1% of the original cohort of 199 
participants) were characterised as longer-term responders where at 6-months, their pain had not returned 
to within 20% of their baseline value. The presence of CWP(RR=0.32;95% CI 0.10–0.98) was associated 
with a reduced likelihood of being a longer-term responder(Table 3). An increased number of pain 
sites(RR=0.83/site;95% CI 0.72–0.97), perceived chronicity of disease(IPQ-B Timeline Score;RR per unit 
increase=0.86;95% CI 0.78-0.94) and depressive symptoms(RR per unit increase=0.89;95% CI 0.81–0.99) 
were also associated with a reduced likelihood of being a longer-term responder(Table 3). Categorisation 
of these variables suggest a linear relationship for both depressive symptoms and timeline score(online 
supplementary Table 3). None of the clinical signs of OA, the use of guided injection or aspiration, or other 
factors linked with short-term response were associated with longer-term response status(Table 3 and 4). 
In a multivariable analysis of the factors associated with longer-term response, only the IPQ-B timeline 
score remained significant after adjustment(online supplementary table 4).
Discussion
In this open-label study of IASI, using OMERACT-OARSI criteria as our definition of response, we found 
several factors associated with short-term response status. Knee tenderness and a stronger belief about 
the effectiveness of treatment were linked with a response to IASI while aspiration of synovial joint fluid and 
having prior ligament or meniscus injury were linked with a reduced risk of response. None of these factors 
though were linked with longer-term response status. In contrast, depressive symptoms and the presence 
of CWP were associated with a reduced risk of being a longer-term responder. 
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Compared to those who did not respond to IASI, those who were short-term responders were more likely to 
have medial tibiofemoral joint tenderness, medial & lateral joint-line tenderness, patellofemoral joint 
tenderness and anserine tenderness. Our findings are in keeping with one study, where clinical 
assessment of local tenderness was linked with an improved response at 3-weeks(OR=1.80;95% CI 1.03-
1.67)31. 
Previous studies do not support the impression that the presence of knee effusion is associated with 
response; with only two32,33 of six studies5,31-35 suggesting that response was better in those with effusion. 
In our study the presence of a clinical effusion(as determined by the bulge sign or ballottement) was not 
associated with treatment response, while aspiration of synovial fluid, if anything was linked with a reduced 
response to IASI. We did not though have information about clinical signs of effusion at follow-up. No other 
symptoms or clinical signs of OA were associated with response. We found in our previous analysis on 
structural predictors to IASI that MRI-effusion and MRI-synovitis were not linked with an improved 
response14,15. Interestingly though among a subsample of subjects in whom synovial fluid(SF) analysis was 
performed, compared to those with a SF WCC in the lowest tertile(<100 cells/mm3) those with WCC in the 
middle and upper tertile had a greater reduction in knee pain following steroid injection36.    
Compared to short-term non-responders, a higher proportion of short-term responders received their 
injection using ultrasound-guided control(41.8% vs 34%). This difference, although not statistically 
significant may, however, be clinically relevant and further large scale studies are needed to confirm 
whether or not ultrasound guidance is linked with an improved outcome. Sibbitt Jr et al.37 reported that 
guided knee injections(compared with blinded injections) were associated with one-month longer of pain-
relief, though guided injections did not lead to better improvement of pain response in the longer-term(6-
months). We did not have objective assessment of localisation of the needle to within the joint and so were 
unable to determine whether accurate localisation within the joint was linked with response. The results of 
a recent study, using air-arthrosonogram as an indicator of accuracy of localisation, however, suggest that 
accurate localisation of IASI to the knee did not result in superior outcome in terms of pain compared to 
inaccurate injection11.
There are few studies which have looked at the influence of adverse psychological factors on treatment 
response. Our null findings for anxiety and depression are in keeping with the study of Jones and Doherty31 
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suggesting no impact on response in the short-term. It is perhaps not surprising, that those who had a 
stronger belief that treatment was going to be effective had a beneficial effect. As we did not have detailed 
information about previous steroid injections to explore whether it was prior experience of a successful 
outcome which may have driven their illness beliefs in relation to treatment response, we cannot exclude 
this possibility. We note though the findings of a recent study in which participants who had had a previous 
experience of injection were less likely to report response to treatment than those undergoing their first 
injection at 9-weeks but not 3-weeks11.
In contrast to our findings on ‘disease’ related factors predicting short-term response, we found no 
evidence that these were linked with longer-term response. We had anticipated that those with more 
marked clinical features of disease such as crepitus and bony enlargement and muscle wasting may also 
have been less likely to be responders; however, this did not appear to be the case.  
A number of factors including CWP, having multiple sites of bodily pain, perceived chronicity of disease 
and depressive symptoms were linked with a reduced likelihood of being a longer-term responder. The 
observation is in keeping with studies suggesting chronic pain, negative attitude and depression can be 
predictors of poorer treatment outcome in other clinical settings38-41. It is possible that altered pain 
sensitivity or awareness of pain as a consequence of the psychological symptoms, may have influenced 
the likelihood of poorer longer-term response. 
There were several limitations to the study. Although this was a comparatively large study, the high 
frequency of the(short-term) response and relatively low frequency of some predictors mean that this study 
was relatively under-powered to detect some predictors of outcome. Further larger studies are needed to 
determine the impact of the putative predictor variables on outcome. Characterisation of the clinical 
predictors was based on clinical examination, which is subject to measurement errors. The effect of errors 
of classification of individual clinical signs due to poor reliability would tend to reduce the chance of finding 
real biological associations–however, formal testing of reliability in the study was good suggesting that this 
is unlikely to have been important in explaining our findings28. Other putative predictor variables were 
obtained largely by self-report and therefore subject to errors of recall; these factors though were obtained 
prior to intervention and it seems unlikely that any such errors would have resulted in bias, though may 
have perhaps led to reduced precision in estimates of effect. There was no placebo group in the trial as the 
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short-term efficacy of IASI in knee OA is already established1-3,5. Whilst it is likely that some of the 
response may be due to a contextual/placebo effect, the trial reflects clinical practice in which injections are 
administered in an ‘open’ setting with the patient aware of the intervention and so the observed ‘predictor’ 
variables are likely to reflect those which would be observed in the clinical setting. Another limitation was 
the possible effect of ‘multiplicity’ as in this study we looked at a range of putative determinants without 
correcting for testing and therefore a risk that some of the predictors found could be circumstantial and for 
which replication of the findings may be needed. The variables, however, which we considered were those 
which we felt could plausibly impact on the outcome. Further it is possible that some real biological 
associations may have been missed(type 2 errors). As outlined earlier, we could not exclude the possibility 
that previous IASI and/or their response may have influenced some of the results. The study was 
performed in predominantly Caucasian population and the results should be generalised beyond this 
setting with caution.  
What are the clinical implications of our findings? Our data suggest there may be a limited role for clinical 
phenotyping in relation to targeting IASI therapy in patients with joint disease though due to the exploratory 
nature of our study, other studies are required to confirm our findings. While knee tenderness was linked 
with an improved response at short-term, the effect was relatively small and unlikely to be of clinical utility; 
short-term response for those with patellofemoral or medial tibiofemoral joint-line tenderness was 86% and 
87.5% compared with 70% and 67% for those without, respectively. The data also suggest that targeting 
therapy based on symptoms including, for example, the presence or absence of a knee effusion should not 
influence the decision about whether or not to undertake the steroid injection. As outlined, psychologic 
factors, including depressive symptoms and presence of widespread pain, and greater number of pain 
sites, although not impacting on short-term outcome, reduced the likelihood of longer-term response; this 
reinforces the importance of targeting these other symptoms in any overall management strategy to reduce 
knee pain due to OA. Based on our data such factors should not influence the decision to treat patients 
with more widespread pain if the target is short-term improvement.  
Conclusion
Among patients with symptomatic knee osteoarthritis, those with knee tenderness are more likely to 
respond to IASI therapy. Clinical signs of knee OA did not, however, predict longer-term response. The 
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presence of CWP, having multiple sites pain and depressive symptoms attenuates longer-term treatment 
response. 
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Figure 1   PRISMA Flow chart of participants  
 
Eligible
N = 209 
Attended 




N = 199 
Responded 
to injection
N = 146 
Withdrawn post-injection 
(N = 8):
• Inflammatory Arthritis = 2
• Adverse  event = 1
• Unrelated serious adverse event = 1
• Left country = 1
• Unable to tolerate MRI / no CE -MRI = 3 
Attended final visit; 
Returned to < 20% of baseline pain 
during observation period 
N = 100 
Did not respond 
to injection
(N = 53) 
Attended final visit;
did not return to < 20% of baseline 
pain during observation period 
(censored at 6 months)
N = 40 
Did not attend final visit
(N = 6):
• Lost to follow up = 2 
• Couldn’t tolerate MRI = 1
• Personal reasons = 3
Withdrawn pre-injection 
(N = 2):
• Knee injection given by GP = 2


















































N¤ Statistic N¤ Statistic N¤ Statistic N¤ Statistic N¤ Statistic
 Demographic / Prior Knee Injury
Age (years), mean (SD) 199 62.8 (10.3) 53 62.6 (9.9) 146 62.9 (10.5) 159 63.4 (10.5) 40 60.5 (9.5)
Females, frequency (%) 199 105 (52.8) 52 22 (41.5) 146 83 (56.9) 159 83 (52.2) 40 22 (55.0)
 Pain 
KOOS-pain subscale score (0-100)*, median (IQR) 199 44.4 (36.1 to 55.6) 53 44.4 (38.9 to 61.1) 146 44.4 (36.1 to 52.8) 159 44.4 (36.1 to 55.6) 40 44.4 (36.1 to 52.8)
Pain on nominated activity VAS (0-10cm)**, median (IQR) 190 7.0 (5.6 to 8.1)¤ 49 7.0 (5.2 to 8.4) 141 7.0 (5.8 to 8.0) 152 7.0 (5.5 to 8.1) 38 7.2 (6.4 to 8.1)
Pain in last w eek VAS (0-10cm)**, median (IQR) 194 6.5 (5.0 to 8.0)¤ 50 6.8 (3.3 to 8.0) 144 6.5 (5.0 to 8.0) 154 6.5 (4.8 to 8.0) 40 6.5 (5.1 to 8.1)
Number of Pain Sites, median (IQR) 177 4.0 (2.0 to 5.0) 47 4.0 (2.0 to 6.0) 130 3.0 (2.0 to 5.0) 143 4.0 (2.0 to 5.0) 34 2.0 (2.0 to 4.0)
Chronic Widespread Pain (ACR), frequency (%) 150 39 (26.0) 38 11 (29.0) 112 28 (25.0) 120 36 (30.0) 30 3 (10.0)
 Psychological factors
HAD – Anxiety, median (IQR) 170 6.5 (3.0 to 9.0) 45 6.0 (3.0 to 9.0) 125 7.0 (3.0 to 9.0) 137 7.0 (3.0 to 9.0) 33 5.0 (2.0 to 9.0)
HAD – Depression, median (IQR) 170 4.0 (2.0 to 8.0) 45 5.0 (3.0 to 8.0) 125 4.0 (2.0 to 7.0) 137 5.0 (2.0 to 8.0) 33 3.0 (2.0 to 6.0)
IPQ-B Consequences Score, median (IQR) 175 6.0 (4.0 to 8.0) 46 7.0 (4.0 to 8.0) 129 6.0 (4.0 to 8.0) 141 7.0 (4.0 to 8.0) 34 6.0 (4.0 to 7.0)
IPQ-B Timeline Score, median (IQR) 172 10.0 (8.0 to 10.0) 46 10.0 (7.0 to 10.0) 126 9.0 (8.0 to 10.0) 139 10.0 (8.0 to 10.0) 33 8.0 (6.0 to 10.0)
IPQ-B Personal Control Score, median (IQR) 173 5.0 (2.0 to 7.0) 45 5.0 (2.0 to 6.0) 128 4.0 (2.0 to 7.0) 140 5.0 (2.0 to 7.0) 33 4.0 (3.0 to 7.0)
IPQ-B Treatment Score, median (IQR) 174 8.0 (5.0 to 10.0) 46 7.0 (5.0 to 8.0) 128 8.0 (6.0 to 10.0) 141 8.0 (5.0 to 10.0) 33 8.0 (7.0 to 9.0)
IPQ-B Identity Score, median (IQR) 175 7.0 (6.0 to 9.0) 46 7.5 (5.0 to 8.0) 129 7.0 (6.0 to 9.0) 142 7.0 (6.0 to 9.0) 33 7.0 (6.0 to 8.0)
IPQ-B Illness Concern Score, median (IQR) 174 7.0 (5.0 to 9.0) 46 7.5 (5.0 to 9.0) 128 7.0 (5.0 to 9.0) 141 7.0 (5.0 to 9.0) 33 7.0 (5.0 to 8.0)
IPQ-B Coherent Score, median (IQR) 172 8.0 (7.0 to 10.0) 46 8.0 (6.0 to 10.0) 126 8.0 (7.0 to 10.0) 139 8.0 (7.0 to 10.0) 33 8.0 (7.0 to 10.0)
IPQ-B Emotional Representation Score, median (IQR) 172 5.0 (2.0 to 7.0) 46 5.0 (2.0 to 8.0) 126 5.0 (2.0 to 7.0) 139 5.0 (2.0 to 7.0) 33 5.0 (1.0 to 7.0)
 Quality of life
SF-12 Physical Component Summary, mean (SD) 184 32.3 (8.7) 50 31.7 (8.8) 134 32.5 (8.7) 147 32.2 (8.9) 37 32.6 (8.0)
SF-12 Mental Component Summary, mean (SD) 184 49.2 (11.7) 50 47.2 (12.8) 134 50.0 (11.2) 147 48.8 (11.8) 37 51.2 (10.9)
 Treatment-Related Factors
Synovial Fluid Aspiration, frequency (%) 199 89 (44.7) 53 32 (60.4) 146 57 (39.0) 159 73 (45.9) 40 16 (40.0)
Ultrasound-guided knee injection, frequency (%) 199 79 (39.7) 53 18 (34.0) 146 61 (41.8) 159 62 (39.0) 40 17 (42.5)
 Clinical-Related Factors (subset n=101†)
Quadriceps Muscle Strength (Nm/kg), median (IQR) 98 0.6 (0.4 to 1.1) 23 0.7 (0.3 to 1.5) 75 0.6 (0.4 to 1.1) 77 0.6 (0.3 to 1.0) 21 1.0 (0.5 to 1.2)
Knee Range of  Movement (degrees), median (IQR)                
Flexion 101 120.0 (111.0 to 127.0) 23 122.0 (106.0 to 127.0) 78 120.0 (112.0 to 127.0) 79 120.0 (111.0 to 126.0) 22 121.0 (114.0 to 128.0)
Extension 101 172.0 (170.0 to 176.0) 23 172.0 (170.0 to 177.0) 78 172.0 (170.0 to 176.0) 79 172.0 (170.0 to 176.0) 22 172.0 (170.0 to 177.0)
*KOOS pain subscale is scored f rom 100 (no pain) to 0 (extreme pain); **VASs are scored f rom 0 (no pain) to 10 (pain as bad as you can imagine); ¤ Where N < 199, this is due to pat ients not  complet ing this particular element of  the quest ionnaire; †Clinical tests were performed in a subset  of  103 patients only, 2 patients did not  complete KOOS 
quest ionnaires, prevent ing their inclusion in the analysis. N = 98 for quadriceps strength due to size of  limb being too large to allow test ing in 3 part icipants; SD = Standard Deviat ion; IQR = Interquart ile Range; SF12 = Short -Form-12; IPQ-B = Illness Perception Questionnaires-Brief; HADS = Hospital Anxiety and Depression scale
Variable
Full Sample Non-Responder Responder Non-Responder Responder
                First Follow Up Visit 6 months Visit



























































Table 1b - Baseline characteristics : clinical examination 
 
Full Sample
Frequency (%) N¤ Frequency (%) N¤ Frequency (%) N¤ Frequency (%) N¤ Frequency (%)
Clinical-Related Factors (subset n=101†)
Previous ligament/meniscus injuries, frequency (%)
no 75 (74.3) 23 11 (47.8) 78 64 (82.1) 79 58 (73.4) 22 17 (77.3)
yes 26 (25.7) 23 12 (52.2) 78 14 (18.0) 79 21 (26.6) 22 5 (22.7)
Crepitus, f requency (%)                                                        
absent 6 (5.9) 23 2 (8.7) 78 4 (5.1) 79 5 (6.3) 22 1 (4.6)
audible and/or palpable 95 (94.1) 23 21 (91.3) 78 74 (94.9) 79 74 (93.7) 22 21 (95.5)
Quadriceps Muscle Wasting, f requency (%)                                          
absent 29 (28.7) 23 9 (39.1) 78 20 (25.6) 79 25 (31.7) 22 4 (18.2)
possible 18 (17.8) 23 1 (4.4) 78 17 (21.8) 79 13 (16.5) 22 5 (22.7)
present 54 (53.5) 23 13 (56.5) 78 41 (52.6) 79 41 (51.9) 22 13 (59.1)
Bony Enlargement, frequency (%)                                                          
absent 54 (53.5) 23 10 (43.5) 78 44 (56.4) 79 40 (50.6) 22 14 (63.6)
unsure 7 (6.9) 23 12 (52.2) 78 28 (35.9) 79 33 (41.8) 22 7 (31.8)
present 40 (39.6) 23 1 (4.4) 78 6 (7.7) 79 6 (7.6) 22 1 (4.6)
Anserine Tenderness, f requency (%)                                                       
absent 76 (75.3) 23 21 (91.3) 78 55 (70.5) 79 60 (76.0) 22 16 (72.7)
present 25 (24.8) 23 2 (8.7) 78 23 (29.5) 79 19 (24.1) 22 6 (27.3)
Patellofemoral Tenderness, frequency (%)                                         
absent 59 (58.4) 23 18 (78.3) 78 41 (52.6) 79 46 (58.2) 22 13 (59.1)
present 42 (41.6) 23 5 (21.7) 78 37 (47.4) 79 33 (41.8) 22 9 (40.9)
Tibiofemoral Tenderness, f requency (%)                                             
absent 44 (43.6) 23 16 (69.6) 78 28 (35.9) 79 37 (46.8) 22 7 (31.8)
medial tibiofemoral joint 10 (9.9) 23 2 (8.7) 78 8 (10.3) 79 6 (7.6) 22 4 (18.2)
lateral tibiofemoral joint 31 (30.7) 23 3 (13.0) 78 28 (35.9) 79 25 (31.7) 22 6 (27.3)
medial & lateral tibiofemoral joint 16 (15.8) 23 2 (8.7) 78 14 (18.0) 79 11 (13.9) 22 5 (22.7)
Ballottementӿ, f requency (%)                                                               
absent 77 (76.2) 23 15 (65.2) 78 62 (79.5) 79 57 (72.2) 22 20 (90.9)
present w ith or w ithout click 24 (23.8) 23 8 (34.8) 78 16 (20.5) 79 22 (27.9) 22 2 (9.1)
Bulge Sign¥, frequency (%)                                                                             
0 35 (34.7) 23 7 (30.4) 78 28 (35.9) 79 27 (34.2) 22 8 (36.4)
trace 35 (34.7) 23 7 (30.4) 78 28 (35.9) 79 27 (34.2) 22 8 (36.4)
1 16 (15.8) 23 4 (17.4) 78 12 (15.4) 79 14 (17.7) 22 2 (9.1)
2 12 (11.9) 23 4 (17.4) 78 8 (10.3) 79 9 (11.4) 22 3 (13.6)
3 3 (3.0) 23 1 (4.4) 78 2 (2.6) 79 2 (2.5) 22 1 (4.6)
 ӿBallot tement test  def ined as posit ive click/ tap or downward movement of  the patella on pressure and rebounding of  patella upon removal of  pressure. ¥0 = no wave produced on down stroke, t race = a small wave on medial side with down stroke, 1 = larger bulge on medial side with down stroke, 2 = spontaneously returned 
to medial side af ter upstroke, 3 = so much fluid that it  was not possible to move the effusion out of  the medial aspect of  the knee. 
Variable
Non-Responder 
First Follow  Up Visit 6 months Visit
Responder Non-Responder  Responder 



































































Number (Number with ultrasound-guided injections) 120 79
Age (years), mean (SD) 62.3 (10.3) 63.5 (10.4)
Females, frequency (%) 62 (51.7) 43 (54.4)
Number of days to follow up appointment, median (IQR) 8.0 (7.0 to 14.0) 8.0 (7.0 to 14.0)
KOOS pain subscale score (0-100)*, median (IQR) 44.4 (36.1 to 55.6) 41. 7 (36.1 to 52.8)
Pain on nominated activity VAS (0-10)**, median (IQR) 7.0 (5.5 to 7.7) ¤ 7.2 (5.8 to 8.4) †
Pain in last week VAS (0-10)**, median (IQR) 6.5 (4.7 to 7.8) ¤ 6.6 (5.3 to 8.3) †
No. of responders to injection, at follow-up visit, frequency (%) 85 (70.8) 61 (77.2)
*KOOS pain subscale is scored from 100 (no pain) to 0 (extreme pain); **VASs are scored from 0 (no pain) to 10 (pain as bad as you can imagine); ¤5 and 3 
participants neglected to complete their pain on nominated activity VAS and pain in last week VAS, respectively; †4 and 2 participants neglected to complete their 
pain on nominated activity VAS and pain in last week VAS, respectively; SD = Standard Deviation; IQR = Interquartile Range
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Table 3 - Short-term and longer-term prediction of response to IASI : Patient and treatment factors
Short-Term Responder (Yes/No) Longer-Term Responder (Yes/No)
Predictor Variable in Regression
N Relative Risk (95% CI) N Relative Risk (95% CI)
Demographic / Prior Knee Injury
Age (per year) 199 1.00 (0.99 to 1.01) 199 0.98 (0.95 to 1.01)
Gender (female vs male [ref.]) 199 1.18 (0.99 to 1.40) 199 1.09 (0.63 to 1.91)
Symptoms
Pain on nominated activity VAS (0-10cm) 190 1.01 (0.96 to 1.06) 190 1.08 (0.91 to 1.27)
Pain in the last week VAS (0-10cm) 194 1.01 (0.97 to 1.05) 194 1.05 (0.92 to 1.21)
Number of Pain Sites (range 0-10) 177 0.98 (0.94 to 1.02) 177 0.83 (0.72 to 0.97)
Chronic Widespread Pain (ACR) 150 0.95 (0.76 to 1.19) 150 0.32 (0.10 to 0.98)
Psychological factors
HAD – Anxiety (0-21) 170 0.99 (0.97 to 1.01) 170 0.93 (0.86 to 1.01)
HAD – Depression (0-21) 170 0.98 (0.95 to 1.01) 170 0.89 (0.81 to 0.99)
IPQ-B Consequences Score (0-10) 175 1.00 (0.97 to 1.04) 175 0.93 (0.83 to 1.05)
IPQ-B Timeline Score (0-10) 172 0.98 (0.95 to 1.02) 172 0.86 (0.78 to 0.94)
IPQ-B Personal Control Score (0-10) 173 1.00 (0.97 to 1.04) 173 0.99 (0.89 to 1.10)
IPQ-B Treatment Score (0-10) 174 1.05 (1.01 to 1.09) 174 1.08 (0.94 to 1.24)
IPQ-B Identity Score (0-10) 175 1.01 (0.97 to 1.06) 175 0.98 (0.85 to 1.13)
IPQ-B Illness Concern Score (0-10) 174 1.00 (0.97 to 1.04) 174 0.95 (0.85 to 1.07)
IPQ-B Coherent Score (0-10) 172 1.03 (0.98 to 1.08) 172 1.12 (0.95 to 1.32)
IPQ-B Emotional Representation Score (0-10) 172 0.99 (0.96 to 1.02) 172 0.97 (0.88 to 1.07)
Quality of life
SF-12 Physical Component Summary (0-100) 184 1.00 (0.99 to 1.01) 184 1.00 (0.97 to 1.04)
SF-12 Mental Component Summary (0-100) 184 1.00 (1.00 to 1.01) 184 1.01 (0.99 to 1.04)
Treatment-Related Factors
Synovial Fluid Aspiration (yes vs no [ref.]) 199 0.79 (0.66 to 0.95) 199 0.82 (0.47 to 1.45)
Ultrasound-guided knee injection  (vs unguided [ref.]) 199 1.09 (0.92 to 1.29) 199 1.16 (0.57 to 2.34)
[ref.] indicates the reference category in the log-binomial regression – e.g. yes vs no [ref.] indicates that ‘no’ was the reference category.
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(Yes/No)Predictor Variable in Regression
Relative Risk (95% CI) Relative Risk (95% CI)
Previous ligament/meniscus injuries, frequency (%)  
No Reference category Reference category
Yes 0.63 (0.44 to 0.91) 0.86 (0.35 to 2.10)
Crepitus¤
Absent Reference category Reference category
Audible and/or palpable 1.17 (0.66 to 2.08) 1.33 (0.21 to 8.26)
Quadriceps Muscle Wasting¤
Absent Reference category Reference category
Possible 1.37 (1.05 to 1.79) 2.01 (0.62 to 6.53)
Present 1.10 (0.83 to 1.47) 1.75 (0.63 to 4.87)
Bony Enlargement¤
Absent Reference category Reference category
Unsure 1.05 (0.76 to 1.46) 0.55 (0.08 to 3.57)
Present 0.86 (0.68 to 1.09) 0.68 (0.30 to 1.52)
Anserine Tenderness
Absent Reference category Reference category
Present 1.27 (1.06 to 1.52) 1.14 (0.50 to 2.59)
Patellofemoral Tenderness
Absent Reference category Reference category
Present 1.27 (1.04 to 1.55) 0.97 (0.46 to 2.06)
Tibiofemoral Tenderness
 Absent Reference category Reference category
Lateral tibiofemoral Joint 1.26 (0.86 to 1.84) 2.51 (0.91 to 6.96)
Medial tibiofemoral Joint* 1.42 (1.10 to 1.82) 1.22 (0.45 to 3.27)
Medial & lateral tibiofemoral joint 1.38 (1.03 to 1.84) 1.96 (0.73 to 5.31)
Ballottement
Absent Reference category Reference category
Present with or without click 0.83 (0.61 to 1.12) 0.32 (0.08 to 1.27)
Bulge Sign¤
0 Reference category Reference category
Trace 1.00 (0.79 to 1.26) 1.00 (0.42 to 2.36)
1 0.94 (0.68 to 1.30) 0.55 (0.13 to 2.29)
2 0.83 (0.54 to 1.28) 1.09 (0.35 to 3.47)
3 0.83 (0.37 to 1.89) 1.46 (0.26 to 8.08)
Quadriceps Muscle Strength (Nm/kg) 0.92 (0.74 to 1.16) 1.45 (0.73 to 2.85)
Knee Range of Movement (degrees)
Flexion (0˚-180˚) 1.00 (0.99 to 1.01) 1.01 (0.98 to 1.04)
Extension (0˚-180˚) 1.00 (0.98 to 1.02) 1.01 (0.94 to 1.09)
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†N=101 in all variables apart quadriceps muscle strength where N=98 due to size of limb being too large to allow testing in 3 
participants. ¤Further testing done using pairwise comparisons for equality by creating dummy variable coding confirms non-
significance. *Further testing done using pairwise comparisons for equality by creating dummy variable coding confirms medial 
tibiofemoral joint tenderness improved response at short-term only. 
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